Telomir Pharmaceuticals is a preclinical-stage biotech company developing a single investigational drug, Telomir-1, a small molecule designed to restore intracellular metal balance — specifically iron, copper, calcium, and zinc. The scientific premise is that dysregulation of these metals drives oxidative stress, mitochondrial dysfunction, and cellular aging, and that correcting this imbalance could address root causes of disease rather than symptoms. Telomir-1 is being evaluated across a wide range of indications, including aging and longevity, Wilson's disease (an orphan drug candidate), Type 2 diabetes, oncology, and age-related macular degeneration, though no lead clinical indication has been selected. All evidence to date is preclinical — from cell lines, nematodes, zebrafish, and rodents — and no human trials have begun. Telomir is targeting an IND submission in 2026, with a Phase 1/2 trial to follow. The company has no revenue, no approved products, and no commercial operations, and funds itself through equity financing. Telomir licenses U.S. patent rights to Telomir-1 from MIRALOGX, a related party, under an exclusive license carrying an 8% royalty on future net sales; non-U.S. rights are held by TELI Pharmaceuticals, another related-party entity that Telomir is in the process of acquiring. The company operates with two part-time employees and relies entirely on third-party research partners to conduct preclinical work.